Cargando…
Scavenger Receptor Class A1 Mediates Uptake of Morpholino Antisense Oligonucleotide into Dystrophic Skeletal Muscle
Exon skipping using phosphorodiamidate morpholino oligomers (PMOs) is a promising treatment strategy for Duchenne muscular dystrophy (DMD). The most significant limitation of these clinically used compounds is their lack of delivery systems that target muscles; thus, cell-penetrating peptides are be...
Autores principales: | Miyatake, Shouta, Mizobe, Yoshitaka, Tsoumpra, Maria K., Lim, Kenji Rowel Q., Hara, Yuko, Shabanpoor, Fazel, Yokota, Toshifumi, Takeda, Shin’ichi, Aoki, Yoshitsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374502/ https://www.ncbi.nlm.nih.gov/pubmed/30763772 http://dx.doi.org/10.1016/j.omtn.2019.01.008 |
Ejemplares similares
-
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2017) -
Evaluation of Amphiphilic Peptide Modified Antisense Morpholino Oligonucleotides In Vitro and in Dystrophic mdx Mice
por: Wang, Mingxing, et al.
Publicado: (2017) -
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018) -
Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: Novak, James S., et al.
Publicado: (2018) -
Antisense PMO Found in Dystrophic Dog Model Was Effective in Cells from Exon 7-Deleted DMD Patient
por: Saito, Takashi, et al.
Publicado: (2010)